Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Graymark Healthcare adds two new sleep centers in Texas, Nebraska

Graymark Healthcare announced that it has added two new sleep centers in Texas and Nebraska with the signing of agreements to provide on-site services to Goodall-Witcher Medical Center in Central Texas and Henderson Community Hospital in Nebraska. These agreements continue to execute on Graymark's strategy to expand the availability of sleep medicine in rural communities that otherwise might not have access to comprehensive sleep care.

30 Jul 2010

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.

16 Jul 2010

Rotech Healthcare accepts 17 CMS contracts in Round 1 Rebid of Medicare Competitive Bidding Program

Rotech Healthcare Inc. today announced that it has accepted 17 contracts awarded by the Centers for Medicare & Medicaid Services in the Round 1 Rebid of the national Medicare Competitive Bidding Program. The Round 1 Rebid included nine metropolitan statistical areas. Only contracted suppliers can service Medicare patients for the competitively-bid product categories in these locations, with a few exceptions. The new contracts awarded in Round 1 have a three-year term and are scheduled to take effect on January 1, 2011.

13 Jul 2010

Sleep apnea may increase risk of heart disease and death by 68%: Study

Obstructive sleep apnea (OSA) that leads to snoring and is actually caused by frequent collapse of the airway during sleep makes it difficult for sufferers to breathe for periods lasting as long as 10 seconds. Severe sufferers may have 30 such apnoeic or breathless episodes per hour that can severely disrupt sleep.

13 Jul 2010

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patients who were denied bariatric surgery for insurance reasons developed a slew of new obesity-related diseases and conditions within three years of follow-up, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

24 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

VIVUS to present data on Qnexa at ENDO meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the Endocrine Society's 92nd Annual Meeting and Expo in San Diego, California. Timothy Garvey, M.D., professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation at the Clinical Trials Symposium on Saturday, June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities."

16 Jun 2010

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Continuous positive airway pressure therapy helps restore memory consolidation in adults with obstructive sleep apnea, suggests a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Children and teens with moderate to severe OSA have lower academic grades: Research

The average academic grades of children and teens with moderate to severe obstructive sleep apnea are worse than the grades of students who have no sleep-disordered breathing, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Excessive sleepiness more common in the U.S. than in Europe: Research

Excessive sleepiness is more common in the U.S. than in Europe, which raises concerns for public health and safety, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Watermark Medical completes $15M equity investment from CA Technologies

Watermark Medical, Inc., a privately-held medical products and services company currently servicing the sleep-disordered breathing market, today announced the completion of a $15 million equity investment from CA Technologies. This equity investment in Watermark Medical represents CA Technologies' entry into the emerging Software-as-a-Service -based healthcare cloud market.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

The prevalence of mild sleep-disordered breathing in young children may fluctuate seasonally, suggests a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Obstructive sleep apnea patients had reductions of grey-matter volume at baseline but showed significant grey-matter volume increase after three months of CPAP therapy, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue severity, and quality of life also remained improved.

5 Jun 2010

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea may help dentists calculate oral appliance treatment success.

5 Jun 2010

Obstructive Sleep Apnea News and Research

Further Reading

VIVUS second-quarter total revenue decreases to $3.9 million

Graymark Healthcare adds two new sleep centers in Texas, Nebraska

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

Rotech Healthcare accepts 17 CMS contracts in Round 1 Rebid of Medicare Competitive Bidding Program

Sleep apnea may increase risk of heart disease and death by 68%: Study

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Data on Qnexa to be featured in six presentations at ADA annual meeting

If you suffer from sleep apnea, consult with your dentist: PDA

VIVUS to present data on Qnexa at ENDO meeting

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Children and teens with moderate to severe OSA have lower academic grades: Research

Excessive sleepiness more common in the U.S. than in Europe: Research

Watermark Medical completes $15M equity investment from CA Technologies

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News